Showing: 1 - 3 of 3 RESULTS

Ontario continues to see COVID-19 cases under 600, with majority under 40

For more on the week’s top stories, and on how the novel coronavirus continues to spread across the country, please refer to our live updates below, as well as our COVID-19 news hub.

17,122 active COVID-19 cases in Canada: 168,960 diagnoses, 9,504 deaths and 142,334 recoveries (as of Oct. 7, 11:00 a.m. ET)

  • Alberta – 1,900 active cases (19,211 total cases, including 281 deaths, 17,030 resolved)

  • British Columbia – 1,384 active cases (9,841 total cases, 244 deaths, 8,184 resolved)

  • Manitoba – 781 active cases (2,246 total cases, 24 deaths, 1,441 resolved)

  • New Brunswick – 5 active cases (205 cases, 2 deaths, 198 resolved)

  • Newfoundland and Labrador – 4 active case (277 total cases, 4 deaths, 269 resolved)

  • Northwest Territories – 0 active cases (5 total cases, 5 resolved)

  • Nova Scotia – 3 active cases (1,089 total cases, 65 deaths 1,021 resolved)

  • Ontario – 5,344 active cases (55,945 total cases, 2,988 deaths, 47,613 resolved)

  • Prince Edward Island – 3 active case (61 total cases, 58 resolved)

  • Quebec –  8,273 active cases (81,914 total cases, 5,906 deaths, 67,735 resolved)

  • Saskatchewan – 139 active cases (1,984 total cases, 24 deaths, 1,821 resolved)

  • Yukon – 0 active cases (15 total cases, 15 resolved)

  • Nunavut – 0 active cases (8 presumptive positive cases)

  • CFB Trenton – 0 active cases (13 total cases, 13 resolved)

Quebec sees first daily COVID-19 under 1,000 in days

Quebec reported 900 new COVID-19 cases on Wednesday, bringing the cumulative total to 81,914.

The province confirmed one death in the past 24 hours, with four deaths occurring between Sept. 30 and Oct. 5, and two additional deaths at an unknown date.

There are 409 people in hospital, an increase of 12 from the previous day, and five more people are in intensive care.

A total of 67,735 have recovered from COVID-19 since the beginning of the pandemic.

Ontario COVID-19 cases remain under 600

Ontario reported 583 new COVID-19 cases on Wednesday, with 173 in Toronto, 121 in Ottawa, 75 in York Region and 70 in Peel.

A total of 60 per cent of the new cases are people under the age of 40.

Since the beginning of the pandemic, Ontario has seen 55,945 COVID-19 cases, with 47,613 resolved.

There have been 2,988 deaths in the province, with one more death reported in the last 24 hours.

In the past day 43,277 tests were conducted in the province, with 55,413 currently under investigation.

For a timeline of all cases prior to today, please visit this page.

Source Article

CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Cancer

Reid’s Stage IV Pancreatic Cancer is Reportedly in “Complete Remission” After Combination Immunotherapy That Included NantKwest’s PD-L1 t-haNK, ImmunityBio’s N-803 and Aldoxorubicin

ImmunityBio and NantKwest Announced in May 2020 That They Planned to Commence a Randomized Phase 2 Study of This Experimental Treatment for Pancreatic Cancer

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted the use of its licensed drug – aldoxorubicin – in the combination immunotherapy used by ImmunityBio, Inc. and NantKwest, Inc. to treat former Senate Majority Leader Harry Reid’s stage IV pancreatic cancer. It was widely reported in June 2020 that former Senator Reid described himself as being in “complete remission” after receiving experimental treatment pioneered by the Chief Executive Officer of ImmunityBio and NantKwest.1

Earlier this year, CytRx highlighted that ImmunityBio and NantKwest announced the initiation of a Phase 2 randomized, two-cohort, open-label study for first and second-line treatment of locally advanced or metastatic pancreatic cancer (QUILT-88). The study received Food and Drug Administration (“FDA”) authorization and was slated to initially enroll 268 subjects across both cohorts. It has been indicated that enrollment was expected to begin in June 2020.

“We wish former Senator Reid the best now that he is reportedly in complete remission and hope that his combination immunotherapy treatment can become the basis for treating other individuals with pancreatic cancer,” said Steven A. Kriegsman, CytRx’s Chairman and CEO. “Although former Senator Reid is only one person and other comprehensive studies and trials are necessary and required, we continue to be encouraged with the progress and results of this promising pancreatic cancer treatment that includes aldoxorubicin.”

CytRx out-licensed global development, manufacturing and commercialization rights for aldoxorubicin to ImmunityBio in 2017. The Company has an agreement with ImmunityBio that can yield up to $343 million in potential milestone payments as well as prospective royalties on sales of aldoxorubicin.

About CytRx Corporation

CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’s most advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx’s other drug candidate, arimoclomol, was sold to Orphazyme A/S (Nasdaq Copenhagen exchange: ORPHA.CO) in exchange for milestone payments and royalties. Orphazyme is testing arimoclomol in four indications including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM). CytRx Corporation’s website is

About Pancreatic Cancer

Pancreatic cancer kills an estimated 47,000 people annually; it is the fourth leading cause of cancer-related death in the U.S., and 57,600 new cases are expected in 2020. Less than 5% of these patients will live for more than five years after diagnosis, and the median survival prognosis is 5 to 8 months. Pancreatic cancer is a disease in which malignant (cancerous) cells form in the tissues of

Majority of Americans say flu shot is best preventative measure, but only this many will get it

Fall is here, meaning the days of cooler weather, changing leaves, and pumpkin spice lattes are ahead. But with the new season also comes the seasonal flu, which this year coincides with the ongoing coronavirus crisis.

As COVID-19 continues to ravage the country, with more than 200,000 American lives claimed by the novel virus, health experts are urging the public to receive a flu vaccine in an effort to prevent hospital systems from becoming inundated with both coronavirus and flu patients.

But the results of a survey commissioned by the National Foundation for Infectious Disease (NFID) and conducted by NORC at the University of Chicago, which were provided to Fox News in advance of its release on Thursday, found that while most participants agreed the vaccine is the best protection against flu, a smaller percentage actually plan to be inoculated.

In a survey of 1,000 adults ages 18 or older from across the country, 68% agreed that receiving the flu vaccine is the “best preventive measure against flu-related deaths and hospitalizations,” up from 61% the year before. (iStock)

In a survey of 1,000 adults ages 18 or older from across the country, 68% agreed that receiving the flu vaccine is the “best preventive measure against flu-related deaths and hospitalizations,” up from 61% the year before. (iStock)

In a survey of 1,000 adults ages 18 or older from across the country, 68% agreed that receiving the flu vaccine is the “best preventive measure against flu-related deaths and hospitalizations,” up from 61% the year before.


But by comparison, only 59% of respondents said they actually plan to be vaccinated against the flu, with 15% saying they are unsure. (For context, 52% of respondents in 2019 said they planned to receive the flu vaccine that year.)

For those who are unsure, some 34% said they do not think flu vaccines work well — a significant decrease from 2019, with 51% of respondents reporting the same — while 32% said that they “never get the flu.” Another 29% said they are concerned about potential side effects of the vaccine, while some 22% said they are concerned about getting the flu from the vaccine (important to note: reactions to the flu shot may include a low-grade fever or muscle aches, but the vaccine cannot cause the flu virus). Additionally, some 17% of respondents said they are unsure about getting the flu shot because they are “concerned about potential exposure to COVID-19 if they go out to get vaccinated.”

Worryingly, nearly one in four respondents (22%) who are considered high-risk for flu-related complications — high-risk groups include those 65 years of age or older, smokers, as well as those with diabetes, asthma, heart disease, or kidney disease — do not plan on getting the flu vaccine this year.

Nearly 60% of White respondents plan to receive the vaccine, while 65% of Hispanics said the same. But some 64% of Black respondents said they do not plan to get the flu shot or are unsure if they will.

As for flu season coinciding with COVID-19, the majority of adults surveyed said they were more concerned about contracting the coronavirus than the